SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

vTv Therapeutics Randomizes First Participant in Cadisegliatin Phase 2a Trial

vTv Therapeutics said the first participant has been randomized in its Phase 2a study of cadisegliatin for type 1 diabetes.

VTVT

Related stories